仅伴有附件或浆膜受累的子宫内膜癌ⅢA期的预后
Outcome of Endometrial Cancer Stage IIIA with Adnexa or Serosal Involvement Only.
作者信息
Jobsen Jan J, Naudin Ten Cate Lambert, Lybeert Marnix L M, Scholten Astrid, van der Steen-Banasik Elzbieta M, van der Palen Job, Stenfert Kroese Marika C, Slot Annerie, Schutter Eltjo M J, Siesling Sabine
机构信息
Department of Radiation Oncology, Medisch Spectrum Twente, Haaksbergerstraat 55, 7513 ER Enschede, The Netherlands.
出版信息
Obstet Gynecol Int. 2011;2011:962518. doi: 10.1155/2011/962518. Epub 2011 May 4.
Objective. The aim of this study is to look at possible differences in outcome between serosa and adnexal involvement stage IIIA endometrial carcinoma. Methods. 67 patients with stage IIIA endometrial carcinoma were included, 46 with adnexal involvement and 21 with serosa. A central histopathological review was performed. Results. The 7-year locoregional failure rate was (LRFR) 2.2% for adnexal involvement and 16.0% for involvement of the serosa (P = .0522). The 7-year distant metastasis-free survival was 72.7% for adnexal involvement and 58.7% for serosa (P = .3994). The 7-year disease-specific survival (DSS) was 71.8% for patients with adnexal involvement and 75.4% for patients with serosa. Conclusion. Endometrial carcinoma stage IIIA with involvement of the adnexa or serosa showed to have a comparable disease-specific survival. Locoregional control was worse for serosa involvement compared to adnexa.
目的。本研究旨在观察ⅢA期子宫内膜癌伴附件受累和伴浆膜受累在预后方面可能存在的差异。方法。纳入67例ⅢA期子宫内膜癌患者，其中46例伴附件受累，21例伴浆膜受累。进行了中心组织病理学复查。结果。伴附件受累患者的7年局部区域失败率（LRFR）为2.2%，伴浆膜受累患者为16.0%（P = 0.0522）。伴附件受累患者的7年无远处转移生存率为72.7%，伴浆膜受累患者为58.75%（P = 0.3994）。伴附件受累患者的7年疾病特异性生存率（DSS）为71.8%，伴浆膜受累患者为75.4%。结论。ⅢA期子宫内膜癌伴附件或浆膜受累的疾病特异性生存率相当。与附件受累相比，浆膜受累的局部区域控制较差。
Zotero 插件